Growth Hormone · GHRP

Ipamorelin

Category: Growth Hormone Secretagogues Last updated 2026-06-19

Ipamorelin at a glance

Ipamorelin is a pentapeptide growth hormone-releasing peptide with high selectivity for GH release and minimal effect on prolactin, cortisol, or appetite. The most-prescribed GHRP in modern peptide protocols. Mechanism: GHRP / GH secretagogue (selective). Typical route: Subcutaneous. FDA status: Not FDA-approved. Dispensed by compounding pharmacies; the most common GHRP in current clinical and telehealth practice.

Drug classGHRP / GH secretagogue (selective)

Half-life~2 hours

RouteSubcutaneous

Common dosing100-300 mcg, 2-3x/day

FDA statusNot approved

Available throughCompounding pharmacies

Mechanism of action

Ipamorelin selectively activates the ghrelin receptor on pituitary somatotrophs, stimulating GH release with minimal off-target effects. Its clean side-effect profile makes it the preferred choice for long-term GH-support protocols, usually paired with CJC-1295.

Dosing reference

Subcutaneous: 100-300 mcg, two to three times daily. Most common protocol is CJC-1295 + Ipamorelin combined at 100 mcg + 100 mcg per dose, taken on empty stomach and before bed.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Dispensed by compounding pharmacies; the most common GHRP in current clinical and telehealth practice.

U.S. telehealth providers that work with Ipamorelin

#1 of 4

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates Ipamorelin.

Read review →

#2 of 4

Marek Health

85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates Ipamorelin.

Read review →

#3 of 4

Maximus

76/100v3.0 six-pillar rubric

Starting at $149/mo. Maximus is one of the providers covered in our editorial directory that dispenses or coordinates Ipamorelin.

Read review →

#4 of 4

Hone Health

80/100v3.0 six-pillar rubric

Starting at $149/mo. Hone Health is one of the providers covered in our editorial directory that dispenses or coordinates Ipamorelin.

Read review →

Related growth hormone secretagogues peptides

Browse the full Growth Hormone Secretagogues category →

Frequently asked questions about Ipamorelin

Why is Ipamorelin combined with CJC-1295?

Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. The two act on different receptors and produce a larger, more sustained GH pulse together than either alone.

Is Ipamorelin safe long-term?

Long-term human safety data is limited. The clean side-effect profile is its primary advantage over other GHRPs, but multi-year use needs to be physician-monitored.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing